Goal: 03 - Sağlık ve Kaliteli Yaşam
Loading...
Description
AMAÇ 3: SAĞLIKLI BİREYLER
Çocuk ölüm oranlarının azaltılması, anne sağlığının iyileştirilmesi, HIV/AIDS, sıtma ve diğer hastalıklar ile mücadelede büyük aşama kaydetmiş durumdayız. 1990 yılından bu yana, önlenebilir çocuk ölümlerinde dünya genelinde %50’yi aşan azalma olmuştur. Anne ölümleri de dünya genelinde %45 azalmıştır. 2000 ile 2013 arasında HIV/AIDS bulaşma oranı %30 azalmış, 6,2 milyonu aşkın insan sıtmadan kurtarılmıştır.
Bu ölümler; önleme ve tedavi, eğitim, aşı kampanyaları, cinsel ve üreme sağlığı hizmetleri vasıtasıyla önlenebilir. Sürdürülebilir Kalkınma Amaçları; AIDS, verem, sıtma ve diğer bulaşıcı hastalık salgınlarını 2030 yılına kadar ortadan kaldırmaya yönelik cesur bir taahhüttür. Amaç, herkesin genel sağlık hizmeti, güvenli ve erişilebilir ilaç ve aşıya kavuşmasını sağlamaktır. Aşı araştırma ve geliştirmelerinin desteklenmesi, bu sürecin vazgeçilmez bir parçasıdır.
10 results
Publication Search Results
Now showing 1 - 10 of 10
Publication Metadata only Palliative Bioresonance Therapy for metastatic cancer patients Metastatik kanser hastalarında palyatif biyorezonans tedavisi(2018-02-01) KIRSEVER, ESRA; KIZILTAN, HURİYE ŞENAY; YILMAZ, RABİYE; BAYIR, AYŞE GÜNEŞ; BAŞIBÜYÜK, MERYEM; ERİŞ, ALİ HİKMET; ÇAKIR, FATMA BETÜL; GÜL, KÜRŞAT; ŞİMŞEK, MUHARREM; KIZILTEPE, AYŞE; GÜMÜŞ, ASLI; KALAYCI, KÜBRA; AKÇAKAYA, ADEM; AYDIN, TEOMAN; AYDOĞDU, İBRAHİM; SÜT, PELİN ALTINOK; MAYADAĞLI, ALPASLAN; KIZILTAN, HURİYE ŞENAY; BAŞIBÜYÜK, MERYEM; ERİŞ, ALİ HİKMET; ÇAKIR, FATMA BETÜL; GÜL, KÜRŞAT; GÜMÜŞ, ASLI; KALAYCI, KÜBRA; AKÇAKAYA, ADEM; AYDIN, TEOMAN; AYDOĞDU, İBRAHİM; MAYADAĞLI, ALPASLANPublication Metadata only Pain management with Radiotherapy and ozone with high dose vitamin C therapy in a case of bone metastatis of breast cancer patient(2018-02-01) KIRSEVER, ESRA; KIZILTAN, HURİYE ŞENAY; YILMAZ, RABİYE; GÜNEŞ BAYIR, AYŞE; BAŞIBÜYÜK, MERYEM; ÇAKIR, FATMA BETÜL; GÜL, KÜRŞAT; ŞİMŞEK, MUHARREM; KIZILTEPE, AYŞE; GÜMÜŞ, ASLI; KALAYCI, KÜBRA; AKÇAKAYA, ADEM; MAYADAĞLI, ALPASLAN; AYDOĞDU, İBRAHİM; ALTINOK SÜT, PELİN; AYDIN, TEOMAN; KIZILTAN, HURİYE ŞENAY; ERİŞ, ALİ HİKMET; GÜNEŞ BAYIR, AYŞE; BAŞIBÜYÜK, MERYEM; ÇAKIR, FATMA BETÜL; GÜL, KÜRŞAT; GÜMÜŞ, ASLI; KALAYCI, KÜBRA; AKÇAKAYA, ADEM; MAYADAĞLI, ALPASLAN; AYDOĞDU, İBRAHİM; ALTINOK SÜT, PELİN; AYDIN, TEOMANPublication Metadata only Metastatik kanser hastalarında palyatif biyorezonans tedavisi(2018-03-11) KIRSEVER, ESRA; KIZILTAN, HURİYE ŞENAY; YILMAZ, RABİYE; BAYIR, AYŞE GÜNEŞ; BAŞIBÜYÜK, MERYEM; ERİŞ, ALİ HİKMET; ÇAKIR, FATMA BETÜL; GÜL, KÜRŞAT; ŞİMŞEK, MUHARREM; KIZILTEPE, AYŞE; GÜMÜŞ, ASLI; KALAYCI, KÜBRA; AKÇAKAYA, ADEM; AYDIN, TEOMAN; AYDOĞDU, İBRAHİM; MAYADAĞLI, ALPASLAN; KIZILTAN, HURİYE ŞENAY; BAŞIBÜYÜK, MERYEM; ERİŞ, ALİ HİKMET; ÇAKIR, FATMA BETÜL; GÜL, KÜRŞAT; GÜMÜŞ, ASLI; KALAYCI, KÜBRA; AKÇAKAYA, ADEM; AYDIN, TEOMAN; AYDOĞDU, İBRAHİM; MAYADAĞLI, ALPASLANPublication Open Access Outcome of Daily Cisplatin with Thoracic Chemoradiotherapy in Advanced Non-small Cell Lung Cancer Patients with Comorbid Disorders: a Pilot Study(2014-01-01) Kiziltan, HURİYE ŞENAY; Bayir, Ayse Gunes; TAŞTEKİN, Didem; Coban, GANİME; Eris, ALİ HİKMET; Aydin, TEOMAN; MAYADAGLI, Alparslan; KIZILTAN, HURİYE ŞENAY; GÜNEŞ BAYIR, AYŞE; ÇOBAN, GANİME; ERİŞ, ALİ HİKMET; AYDIN, TEOMAN; MAYADAĞLI, ALPASLANBackground: Lung cancer is the most common cancer in males worldwide. The principal mode of treatment in the early stage of non-small cell lung cancer (NSCLC) is surgery. However, five-year survival is only about 15% for all stages. The aim is to investigate the effect of daily low dose cisplatin concurrently with radiation therapy in advanced NSCLC patients with poor performance status. Materials and Methods: Ten patients diagnosed as inoperable Stage IIIB NSCLC with comorbid disease were assessed retrospectively in Bezmialem Vakif University, Faculty of Medicine, Department of Radiation Oncology, between 2011 to 2013. ECOG performance status was between 3 and 4. Cisplatin was administered at 6mg/m2 daily, for 5 days a week concurrently with radiotherapy using 160-200 cGy daily fractions, 54 Gy being the lowest and 63 Gy being the highest dose. Results: Complete response at the primary tumour site was obtained in 20% patients. Grade I esophagitis was seen 70 percent of patients, and the grade II haematological toxicity rate was 20 %. Median survival time was 7 months. Conclusions: Median survival time was reasonable, despite the patients ECOG performance status of 3-4, which is similar to groups even without comorbid disorders in comparison to other published papers in the literature. Acceptable toxicity, high response rates and quality of life of patients are the other favourable features.Publication Metadata only Düşük doz radyoterapi volümlerinin akciğer kanseri hastalarında yaşam üzerine etkileri(2017-07-01) KIZILTAN, HURİYE ŞENAY; MAYADAĞLI, ALPASLAN; ERİŞ, ALİ HİKMET; KABLAN, ÖZGÜR; EROĞUZ, SEZGİ TURAN; EVRİM, EVREN; ALTINOK SÜT, PELİN; TEKÇE, ERTUĞRUL; GÜNEŞ BAYIR, AYŞE; KIRSEVER, ESRA; KIZILTAN, HURİYE ŞENAY; MAYADAĞLI, ALPASLAN; ERİŞ, ALİ HİKMET; KABLAN, ÖZGÜR; ALTINOK SÜT, PELİN; TEKÇE, ERTUĞRUL; GÜNEŞ BAYIR, AYŞEPublication Metadata only Radioprotectant and Cytotoxic Effects of Spirulina in Relapsed Verrucous Vulvar Cancer: A Case Report(2015-01-01) Kiziltan, HURİYE ŞENAY; Bayir, Ayse Gunes; TAŞPINAR, Ozgur; Yucesan, GÜL; Tastekin, Didem; SONMEZ, Fatma Cavidan; Coban, GANİME; Kilic, GÖKHAN; Eris, ALİ HİKMET; Aydin, TEOMAN; Akcakaya, ADEM; Mayadagli, ALPASLAN; KIZILTAN, HURİYE ŞENAY; GÜNEŞ BAYIR, AYŞE; YÜCESAN, GÜL; ÇOBAN, GANİME; KILIC, GÖKHAN; ERİŞ, ALİ HİKMET; AYDIN, TEOMAN; AKÇAKAYA, ADEM; MAYADAĞLI, ALPASLANContext . The treatment of relapsed verrucous vulvar cancer (VVC) is difficult. When vulvar cancer relapses, the treatment response is low for second-line treatments. Conversely, toxicity is high. Therefore, scientists need to identify different treatment methods.Publication Metadata only Can low-dose radiotherapy volumes be one of the contributing factors to early relapses in lung cancer patients?(2018-03-01T00:00:00Z) Kiziltan, Huriye Senay; MAYADAĞLI, Alpaslan; TEKÇE, ERTUĞRUL; ERİŞ, ALİ HİKMET; Kablan, Ozgur; Altinok Sut, Pelin; KIZILTAN, HURİYE ŞENAY; MAYADAĞLI, ALPASLAN; TEKÇE, ERTUĞRUL; ERİŞ, ALİ HİKMET; KABLAN, ÖZGÜR; ALTINOK SÜT, PELİN© 2018 The Authors. Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.Objective: Several studies have shown that low-dose radiotherapy (RT) might increase tumor invasion and metastases. Whereas multiple RT fields that increase low-dose RT areas are often used to prevent damage to organs at risk. We carried out a clinical trial with the concern that low-dose RT sites could increase invasions or metastases when multiple sites were used. Methods: A clinical retrospective study was carried out on 50 lung cancer patients with stage II–IIIB cancer, who underwent RT and/or chemotherapy, had Eastern Cooperative Oncology Group performances 1–3, were aged 45–87 years, and without metastases. RT was carried out for 5 days with 180–200 cGy fractions per day with a total dose of 54–66 Gy. The radiation dose volume areas V5, V10, V20, V40, V50, and V60 of lung were calculated and analyzed by Mann–Whitney U-test and L par test on disease-free and overall survival statistically. Results: It was determined that V5, V10, and V20, which constitute the low RT dose areas of the lung, positively affected the recurrence-free and overall survival minimally according to r correlation values. Conclusion: Low-dose RT volumes were positively affected minimally by recurrence-free survival and overall survival in the present study. The effects of low-dose radiation must be evaluated more clearly in studies.Publication Metadata only Can Nigella Sativa and Pure Honey Improved Chemoradiotherapy Effects in Advanced Pancreatic Cancer(2017-12-01) KIZILTAN, HURİYE ŞENAY; KÜRŞAT, TÜRKDOĞAN; GÜNEŞ BAYIR, AYŞE; ERİŞ, ALİ HİKMET; MAYADAĞLI, ALPASLAN; KIZILTAN, HURİYE ŞENAY; GÜNEŞ BAYIR, AYŞE; ERİŞ, ALİ HİKMET; MAYADAĞLI, ALPASLANPublication Open Access Effects of Low-Dose Radiation on the Survival of Lung Cancer Patients(2018-04-01) Kiziltan, HURİYE ŞENAY; Mayadagli, ALPASLAN; Eris, ALİ HİKMET; Kablan, Ozgur; TURAN, Sezgi; EVREN, Evrim; SUT, Pelin Altinok; Tekce, ERTUĞRUL; BAYIR, Ayse Gunes; KIRSEVER, Esra; KIZILTAN, HURİYE ŞENAY; MAYADAĞLI, ALPASLAN; ERİŞ, ALİ HİKMET; KABLAN, ÖZGÜR; TEKÇE, ERTUĞRULObjective: Some previous studies have shown that low-dose radiotherapy (RT) can increase tumor invasion and metastasis. Multiple RT fields are usually used to prevent the damage to the organs at risk. We performed a clinical study with a concern that low-dose RT might increase invasion or metastasis. Ionizing radiation (IR) can enhance the potential tumor micro-environment by modifying the host micro-metastatic cancer cells.Publication Open Access Importance of Performing Radiotherapy and Chemotherapy in the Same Clinic and Bad Prognostic Factors for Small-cell Lung Cancer Patients(2016-01-01) KIZILTAN, HURİYE ŞENAY; MAYADAĞLI, ALPASLAN; TAŞTEKİN, DİDEM; TAŞPINAR, ÖZGÜR; ERİŞ, ALİ HİKMET; ISMAYLOVA, MEDİNA; KIZILTAN, HURİYE ŞENAY; MAYADAĞLI, ALPASLAN; ERİŞ, ALİ HİKMETObjective: We evaluated different treatment results reported and showed the effect of treatment at single and multiple clinics for small-cell lung cancer (SCLC). We attempted to show a decreasing impact of chemotherapy (CT) and thoracic radiotherapy (RT) treatment results when implemented at different clinics for SCLC compared to the treatment results at a clinic. Methods: We conducted a retrospective study on 54 non-metastatic SCLC patients who underwent treatments at various clinics. Patients underwent 1–12 courses of CT before they came to the clinic for thoracic RT. RT was performed at 180–400 cGy dose per fraction for a total of 30–52 Gy doses, and patients were followed for 12–60 months. Results: When the study was reviewed, the results showed that the median disease-free survival and survival rates were 8 and 9 months and that the 2-, 5-, and 5-year survival rates were 8%, 6.3%, and 1.8%, respectively. The median progression-free survival rates for 2 and 3 years were 4%, and for 5 years, it was 1.8%. Weight loss for disease-free survival (p=0.01) and superior vena cava syndrome for overall survival (p=0.02) were considered as bad prognostic factors. In this study, acceptable toxicity values were found when the results were compared with those from other studies. Conclusion: We obtained worse results than those from literature data on our SCLC patients who came to our clinic after the progression of their disease. The main causes were identified as insufficient staging and different treatment protocols applied at different clinics. Therefore, we argue that CT and thoracic RT for SCLC must be performed at the same clinic and that the same protocols and staging methods must be used.